An anonymous reader quotes a report from NPR: Hospital staff are forced to write notes by hand and deliver orders for tests and prescriptions in person in the ongoing fallout from a recent ransomware attack at the national health system Ascension. Ascension is one of the largest health systems in the United States, with some 140 hospitals located across 19 states and D.C. A spokesperson said in a statement that "unusual activity" was first detected on multiple technology network systems Ascension uses on Wednesday, May 8. Later, representatives confirmed that some of Ascension's electronic health records systems had been affected, along with systems used "to order certain tests, procedures and medications."

Some phone capabilities have also been offline, and patients have been unable to access portals used to view medical records and get in touch with their doctors. Due to these interruptions, hospital staff had to shift to "manual and paper based" processes. "Our care teams are trained for these kinds of disruptions and have initiated procedures to ensure patient care delivery continues to be safe and as minimally impacted as possible," an Ascension spokesperson said in a May 8 statement. Kris Fuentes, who works in the neonatal intensive care unit at Ascension Seton Medical Center in Austin, said she remembers when paper charting was the norm. But after so many years of relying on digital systems, she said her hospital wasn't ready to make such an abrupt shift. "It's kind of like we went back 20 years, but not even with the tools we had then," Fuentes said. "Our workflow has just been really unorganized, chaotic and at times, scary."

Fuentes said orders for medication, labs and imaging are being handwritten and then distributed by hand to various departments, whereas typically these requests are quickly accessed via computer. A lack of safety checks with these backup methods has introduced errors, she said, and every task is taking longer to complete. "Medications are taking longer to get to patients, lab results are taking longer to get back," she said. "Doctors need the lab results, often, to decide the next treatment plan, but if there's a delay in access to the labs, there's a delay in access to the care that they order." As of Tuesday, Ascension still had no timeline for when the issues might be resolved, and reported that it continued to work with "industry-leading cybersecurity experts" to investigate the ransomware attack and restore affected systems. The FBI and Cybersecurity and Infrastructure Security Agency are also involved in the investigation. "While Ascension facilities remain open, a health system representative said on May 9 that in some cases, emergency patients were being triaged to different hospitals, and some non-emergent appointments and procedures were postponed," reports NPR. "Certain Ascension pharmacies are not operational, and patients are being asked to bring in prescription bottles or numbers."

"Individuals who are enrolled in Ascension health insurance plans are being directed to mail in monthly payments while the electronic payment system is down."

Hybrid and electric cars are more likely to hit pedestrians than petrol or diesel vehicles, due to their quieter engines that make them harder for pedestrians to hear. Other contributing factors include the tendency for drivers of electric cars to be younger and less experienced, and the vehicles' heavier weight and swift acceleration, increasing stopping distances. The Guardian reports: Data from 32 billion miles of battery-powered car travel and 3 trillion miles of petrol and diesel car trips showed that mile-for-mile electric and hybrid cars were twice as likely to hit pedestrians than fossil fuel-powered cars, and three times more likely to do so in urban areas. "Electric cars are a hazard to pedestrians because they are less likely to be heard than petrol or diesel cars," said Phil Edwards, first author on the study and professor of epidemiology and statistics at the London School of Hygiene & Tropical Medicine. "The government needs to mitigate these risks if they are going to phase out the sale of petrol and diesel cars." "If you're moving to an electric car, remember it's a new kind of vehicle," Edwards added. "They are much quieter than the old-fashioned cars, and pedestrians have learned to navigate roads by listening for traffic. Drivers of these vehicles need to be extra cautious."

Most vehicles on the road are petrol or diesel and these were involved in three-quarters of pedestrian collisions. But for the same distance travelled, battery-powered cars were more dangerous. The average annual pedestrian casualty rate per 100m miles travelled was 5.16 for electric and hybrid cars compared with 2.4 for petrol and diesel cars, according to the study in the Journal of Epidemiology and Community Health. In rural settings, battery-powered cars were no more dangerous than petrol or diesel, but in towns and cities they were three times more likely to collide with pedestrians, the researchers found. Since July 2019, all new hybrid and electric vehicles sold in Europe have been required to have an acoustic vehicle alerting system that emits sound when the car is travelling slowly, but there are hundreds of thousands of electric cars on the road without the devices. "If government made sure these systems were installed in all electric vehicles and retrofitted them to older electric cars, that would be a good start," Edwards said, adding that the Green Cross Code also "probably needs updating."

The FDA has approved Neuralink to implant its brain chip in a second patient. According to the Wall Street Journal, the company also outlined fixes to an electrode problem that caused its chip to detach from the first patient's brain. They were unharmed and could still control a computer mouse using their thoughts. Axios reports: Neuralink, which is owned by Elon Musk, said it is seeking applications for another patient with quadriplegia to test if the device can allow a person to do tasks like control a phone and computer. It outlined fixes that included embedding some of the device's wiring deeper into the brain, the Wall Street Journal reported, citing a document and a person familiar with the company.

Neuralink rival Synchron is preparing a large-scale clinical trial with an eye toward seeking commercial approval of its implant. Mass General Brigham has also launched a collaborative effort with stakeholders and the FDA to accelerate the development of the implanted devices.

An anonymous reader quotes a report from Medical Xpress: A team of medical researchers at the National Children's Medical Center, Children's Hospital, Fudan University, in China, has developed a technique to freeze and thaw brain tissue without causing damage. In their study, published in the journal Cell Reports Methods, the group tested bathing brain organoid tissue in candidate chemicals before freezing them using liquid nitrogen. [...] The work involved dipping or soaking brain organoids (brain tissue grown from stem cells) in candidate compounds and then freezing and thawing them to see how they fared. After many attempts, they found one combination of solutions that worked best -- a mix of ethylene glycol, methylcellulose DMSO and Y27632. They named the solution mix MEDY.

The research team then tested MEDY under a variety of conditions to see how well it prevented damage from freezing. The conditions involved changing variables, such as the age of the organoids prior to freezing and how long they were soaked in a MEDY solution. They then allowed the organoids to resume growing after they were thawed for up to 150 days. The researchers found little difference between organoids that had been frozen and those that had not -- even those that had been frozen for as long as 18 months. As a final test, the research team used their technique on a sample of brain tissue obtained from a live human patient and found that it worked just as well.

An anonymous reader shares a report: Hims & Hers Health, one of the online pharmacies that got its start prescribing dick pills, is now offering knockoff versions of GLP-1 weight loss drugs. Hims & Hers says it will offer drugs that mimic Ozempic and Wegovy, the active ingredient of which is semaglutide. The copycat versions are made by compounding pharmacies. The formulations aren't the same as the FDA-approved versions of the drug and haven't been directly evaluated by the FDA, either. But they're cheaper than the real thing: $199 a month, compared to the branded version, which can cost more than $1,000 a month without insurance.

Compounding pharmacies can make knockoff versions of branded drugs when they are in shortage, as the GLP-1 drugs -- prescribed for diabetes and weight loss -- currently are. The FDA has already received reports of adverse events for compounded versions of semaglutide. Hims & Hers says it "conducted extensive research for over a year" into finding a supplier, but does not name the one it chose to partner with. "Over the last year, we have grown in our conviction -- based on our medical experts' evaluation and the strength of our infrastructure -- that if done properly, compounded GLP-1s are safe and effective," the company said in its statement.

An anonymous reader quotes a report from The Guardian: Proteins in the blood could warn people of cancer more than seven years before it is diagnosed, according to research [published in the journal Nature Communications]. Scientists at the University of Oxford studied blood samples from more than 44,000 people in the UK Biobank, including over 4,900 people who subsequently had a cancer diagnosis. They compared the proteins of people who did and did not go on to be diagnosed with cancer and identified 618 proteins linked to 19 types of cancer, including colon, lung, non-Hodgkin lymphoma and liver.

The study, funded by Cancer Research UK and published in Nature Communications, also found 107 proteins associated with cancers diagnosed more than seven years after the patient's blood sample was collected and 182 proteins that were strongly associated with a cancer diagnosis within three years. The authors concluded that some of these proteins could be used to detect cancer much earlier and potentially provide new treatment options, though further research was needed.

An anonymous reader quotes a report from CBS News: Richard "Rick" Slayman, the first human to receive a genetically modified pig kidney transplant, has died almost two months after the procedure. Slayman, who had end-stage kidney disease, underwent the transplant in March at Massachusetts General Hospital in Boston at age 62. The hospital said in a statement on Saturday that there was "no indication" that his death was the result of the transplant. The transplant surgeon had said he hoped the transplant would function for at least two years.

"The Mass General transplant team is deeply saddened at the sudden passing of Mr. Rick Slayman," read the hospital statement. "Mr. Slayman will forever be seen as a beacon of hope to countless transplant patients worldwide and we are deeply grateful for his trust and willingness to advance the field of xenotransplantation." The surgery was a milestone for the field of xenotransplantation -- the transplant of organs from one species to another -- as a way to alleviate the organ shortage for people who need transplants. The effort to genetically modify animal organs is in hopes that the human body will not reject the foreign tissue. NPR notes that there are more than 100,000 people in the U.S. on the waitlist for organs.

Brian Shelton's type 1 diabetes was treated with an infusion of insulin-producing pancreas cells (grown from stem cells). In 2021, the New York Times reported: Now his body automatically controls its insulin and blood sugar levels. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes. "It's a whole new life," Shelton said. Diabetes experts were astonished but urged caution. The study is continuing and will take five years, involving 17 people with Type 1 diabetes.
"By fall 2023, three patients, including Shelton, had achieved insulin independence by day 180 post-transplant," MedScape reported (in January of 2024): In the phase 1/2 study, 14 patients with type 1 diabetes and impaired hypoglycemia awareness or recurrent hypoglycemia received portal vein infusions of VX-880 [Vertex Pharmaceutical's pancreatic islet cell replacement therapy] along with standard immunosuppression. As of the last data cut, all 14 patients demonstrated islet cell engraftment and production of endogenous insulin. After more than 90 days of follow-up, 13 of the patients have achieved A1c levels < 7% without using exogenous insulin.
Brian Shelton and another patient died, and while Vertex says their deaths were unrelated to the treatment, they have "placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators." (MedScape adds that Vertex "is continuing with a phase 1/2 clinical trial of a different product, VX-264, which encapsulates the same VX-880 cells in a device designed to eliminate the need for immunosuppression.")

And meanwhile, a new study in China (again using stem cell-derived islet tissue) has provided "encouraging evidence that islet tissue replacement is an effective cure for diabetic patients," the researchers wrote in Nature. The treatment was administered to 59-year-old, type-2 diabetic.

"Marked changes in the patient's glycemic control were observed as early as week 2," the researchers write, and after week 32, the patient's Time In Tight Range (TITR) "had readily reached 99% and was maintained thereafter."

Thanks to long-time Slashdot reader hackingbear for sharing the news.

An anonymous reader quotes a report from Interesting Engineering: Imagine exploring the intricate world within a single cubic millimeter of human brain tissue. It might seem insignificant, but within that tiny space lies a universe of complexity -- 57,000 individual cells, 230 millimeters of blood vessels, and a staggering 150 million synapses, the junctions where neurons communicate. All this information translates to a mind-boggling 1,400 terabytes of data. That's the kind of groundbreaking achievement researchers from Harvard and Google have just accomplished.

Leading the charge at Harvard is Professor Jeff Lichtman, a renowned expert in brain structure. Partnering with Google AI, Lichtman's team has co-created the most detailed 3D reconstruction of a human brain fragment to date. This intricate map, published in Science, offers an unprecedented view of the human temporal cortex, the region responsible for memory and other higher functions. Envision a piece of brain tissue roughly half the size of a rice grain but magnified to reveal every cell and its web of neural connections in vivid detail. This remarkable feat is the culmination of nearly a decade of collaboration between Harvard and Google. Lichtman's expertise in electron microscopy imaging is combined with Google's cutting-edge AI algorithms. [...]

The newly published map in Science reveals previously unseen details of brain structure. One such discovery is a rare but powerful set of axons, each connected by up to 50 synapses, potentially influencing a significant number of neighboring neurons. The team also encountered unexpected structures, like a small number of axons forming intricate whorls. Since the sample came from a patient with epilepsy, it's unclear if these formations are specific to the condition or simply uncommon occurrences.

Ancient Slashdot reader jd shares a report from The Guardian: Neuralink's first attempt at implanting its chip in a human being's skull hit an unexpected setback after the device began to detach from the patient's brain, the company revealed on Wednesday. The patient, Noland Arbaugh, underwent surgery in February to attach a Neuralink chip to his brain, but the device's functionality began to decrease within the month after his implant. Some of the device's threads, which connect the miniature computer to the brain, had begun to retract. Neuralink did not disclose why the device partly retracted from Arbaugh's brain, but stated in a blog post that its engineers had refined the implant and restored functionality.

The decreased capabilities did not appear to endanger Arbaugh, and he could still use the implant to play a game of chess on a computer using his thoughts, according to the Wall Street Journal, which first broke the news of the issue with the chip. The possibility of removing the implant was considered after the detachment came to light, the Journal reported. [...] Arbaugh praised the implant during a demonstration in March and said that it had "already changed his life," while also stating that it had not been perfect and they "have run into some issues."

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic. From a report: The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied. According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

Pam Belluck reports via the New York Times: Scientists are proposing a new way of understanding the genetics of Alzheimer's that would mean that up to a fifth of patients would be considered to have a genetically caused form of the disease. Currently, the vast majority of Alzheimer's cases do not have a clearly identified cause. The new designation, proposed in a study published Monday, could broaden the scope of efforts to develop treatments, including gene therapy, and affect the design of clinical trials. It could also mean that hundreds of thousands of people in the United States alone could, if they chose, receive a diagnosis of Alzheimer's before developing any symptoms of cognitive decline, although there currently are no treatments for people at that stage. The new classification would make this type of Alzheimer's one of the most common genetic disorders in the world, medical experts said.

"This reconceptualization that we're proposing affects not a small minority of people," said Dr. Juan Fortea, an author of the study and the director of the Sant Pau Memory Unit in Barcelona, Spain. "Sometimes we say that we don't know the cause of Alzheimer's disease," but, he said, this would mean that about 15 to 20 percent of cases "can be tracked back to a cause, and the cause is in the genes." The idea involves a gene variant called APOE4. Scientists have long known that inheriting one copy of the variant increases the risk of developing Alzheimer's, and that people with two copies, inherited from each parent, have vastly increased risk.

The new study, published in the journal Nature Medicine, analyzed data from over 500 people with two copies of APOE4, a significantly larger pool than in previous studies. The researchers found that almost all of those patients developed the biological pathology of Alzheimer's, and the authors say that two copies of APOE4 should now be considered a cause of Alzheimer's -- not simply a risk factor. The patients also developed Alzheimer's pathology relatively young, the study found. By age 55, over 95 percent had biological markers associated with the disease. By 65, almost all had abnormal levels of a protein called amyloid that forms plaques in the brain, a hallmark of Alzheimer's. And many started developing symptoms of cognitive decline at age 65, younger than most people without the APOE4 variant.

In a first for "digital health technology," the Apple Watch's atrial fibrillation (AFib) history feature has been approved by the FDA to join the FDA's Medical Device Development Tools (MDDT) program. This means the wearable is now usable in clinical studies. The Verge reports: The FDA announcement describes using it as a noninvasive way to collect the data both before and after treatment: "Designed to be used as a biomarker test to help evaluate estimates of AFib burden as a secondary effectiveness endpoint within clinical studies intended to evaluate the safety and effectiveness of cardiac ablation devices to treat."

An anonymous reader quotes a report from Techdirt: Last week, hundreds of nurses protested the implementation of sloppy AI into hospital systems in front of Kaiser Permanente. Their primary concern: that systems incapable of empathy are being integrated into an already dysfunctional sector without much thought toward patient care: "No computer, no AI can replace a human touch," said Amy Grewal, a registered nurse. "It cannot hold your loved one's hand. You cannot teach a computer how to have empathy."

There are certainly roles automation can play in easing strain on a sector full of burnout after COVID, particularly when it comes to administrative tasks. The concern, as with other industries dominated by executives with poor judgement, is that this is being used as a justification by for-profit hospital systems to cut corners further. From a National Nurses United blog post (spotted by 404 Media): "Nurses are not against scientific or technological advancement, but we will not accept algorithms replacing the expertise, experience, holistic, and hands-on approach we bring to patient care," they added.

Kaiser Permanente, for its part, insists it's simply leveraging "state-of-the-art tools and technologies that support our mission of providing high-quality, affordable health care to best meet our members' and patients' needs." The company claims its "Advance Alert" AI monitoring system -- which algorithmically analyzes patient data every hour -- has the potential to save upwards of 500 lives a year. The problem is that healthcare giants' primary obligation no longer appears to reside with patients, but with their financial results. And, that's even true in non-profit healthcare providers. That is seen in the form of cut corners, worse service, and an assault on already over-taxed labor via lower pay and higher workload (curiously, it never seems to impact outsized high-level executive compensation).

New submitter berghem shares a report from The Guardian: For the first time, researchers have formally shown that exposure to toxic PFAS increases the likelihood of death by cardiovascular disease, adding a new level of concern to the controversial chemicals' wide use. The findings are especially significant because proving an association with death by chemical exposure is difficult, but researchers were able to establish it by reviewing death records from northern Italy's Veneto region, where many residents for decades drank water highly contaminated with PFAS, also called "forever chemicals." Records further showed an increased likelihood of death from several cancers, but stopped short of establishing a formal association because of other factors. [...]

Veneto's drinking water was widely contaminated by a PFAS-production plant between 1985 and 2018. Researchers first found an excess of about 4,000 deaths during this period, or about one every three days. Part of the region was supplied with water from a different source, giving researchers the opportunity to compare records for tens of thousands of people who drank contaminated water and lived near those who did not. Though PFAS can affect the cardiovascular system in different ways, it is largely a problem because it produces stubbornly high and dangerous levels of cholesterol. The levels are difficult to control because they aren't caused by dietary or lifestyle choices that can be addressed with adjustments, but hormonal changes that affect the metabolism and the body's ability to control plaque in arteries. The study's authors suspect that post-traumatic stress disorder caused by the environmental disaster, which upended lives across the region, may also be contributing to circulatory disease. The evidence of a jump in kidney cancer was also "very clear," [said Annibale Biggeri, the peer-reviewed study's lead author, and a researcher with the University of Padua]. In the study's first five years, 16 cases were recorded, while 65 were recorded in the last five years. It also found elevated levels of testicular cancer during some time periods.

The records "showed clearly" that earlier life exposures led to higher levels of mortality, except for women who have multiple children. Previous research has found levels were higher in women with only one child. The chemicals accumulate in placentas and are passed on to children during pregnancy, which reduces levels in the body. Mortality levels among women who were of child-bearing age were generally lower, but increased in older women. The chemicals will be passed down to children for generations, said Laura Facciolo, a Veneto resident who drank contaminated water. She said the findings underscore the need to ban PFAS, and the disaster's injustice. The findings have been published in the journal Environmental Health.

Walmart isn't making enough money off its new health centers, so it decided to close up shop. From a report: The retail giant announced today that it'll shutter all 51 health centers it opened up across five states since 2019. Walmart is also getting rid of its virtual care program after acquiring telehealth provider MeMD in 2021. "We determined there is not a sustainable business model for us to continue," Walmart said in an announcement today.

"This is a difficult decision, and like others, the challenging reimbursement environment and escalating operating costs create a lack of profitability that make the care business unsustainable for us at this time," Walmart said today. It's an about-face from last year when Walmart said it planned to double its number of health clinics and expand into two new states in 2024.

Abstract of a paper on National Bureau of Economic Research: Physicians commonly receive marketing-related transfers from drug firms. We examine the impact of these relationships on the prescribing of physician-administered cancer drugs in Medicare. We find that prescribing of the associated drug increases 4\% in the twelve months after a payment is received, with the increase beginning sharply in the month of payment and fading out within a year. A marketing payment also leads physicians to begin treating cancer patients with lower expected mortality. While payments result in greater expenditure on cancer drugs, there are no associated improvements in patient mortality.

An anonymous reader quotes a report from The Guardian: Hospitals -- despite being places where people implicitly expect to have their personal details kept private -- frequently use tracking technologies on their websites to share user information with Google, Meta, data brokers, and other third parties, according to research published today. Academics at the University of Pennsylvania analyzed a nationally representative sample of 100 non-federal acute care hospitals -- essentially traditional hospitals with emergency departments -- and their findings were that 96 percent of their websites transmitted user data to third parties. Additionally, not all of these websites even had a privacy policy. And of the 71 percent that did, 56 percent disclosed specific third-party companies that could receive user information.

The researchers' latest work builds on a study they published a year ago of 3,747 US non-federal hospital websites. That found 98.6 percent tracked and transferred visitors' data to large tech and social media companies, advertising firms, and data brokers. To find the trackers on websites, the team checked out each hospitals' homepage on January 26 using webXray, an open source tool that detects third-party HTTP requests and matches them to the organizations receiving the data. They also recorded the number of third-party cookies per page. One name in particular stood out, in terms of who was receiving website visitors' information. "In every study we've done, in any part of the health system, Google, whose parent company is Alphabet, is on nearly every page, including hospitals," [Dr Ari Friedman, an assistant professor of emergency medicine at the University of Pennsylvania] observed. "From there, it declines," he continued. "Meta was on a little over half of hospital webpages, and the Meta Pixel is notable because it seems to be one of the grabbier entities out there in terms of tracking."

Both Meta and Google's tracking technologies have been the subject of criminal complaints and lawsuits over the years -- as have some healthcare companies that shared data with these and other advertisers. In addition, between 20 and 30 percent of the hospitals share data with Adobe, Friedman noted. "Everybody knows Adobe for PDFs. My understanding is they also have a tracking division within their ad division." Others include telecom and digital marketing companies like The Trade Desk and Verizon, plus tech giants Oracle, Microsoft, and Amazon, according to Friedman. Then there's also analytics firms including Hotjar and data brokers such as Acxiom. "And two thirds of hospital websites had some kind of data transfer to a third-party domain that we couldn't even identify," he added. Of the 71 hospital website privacy policies that the team found, 69 addressed the types of user information that was collected. The most common were IP addresses (80 percent), web browser name and version (75 percent), pages visited on the website (73 percent), and the website from which the user arrived (73 percent). Only 56 percent of these policies identified the third-party companies receiving user information. In lieu of any federal data privacy law in the U.S., Friedman recommends users protect their personal information via the browser-based tools Ghostery and Privacy Badger, which identify and block transfers to third-party domains.

A brain implant startup called Synchron is preparing to recruit patients for a large-scale clinical trial to seek commercial approval for its device. Reuters reports: Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview. "Part of this registry is to start to enable local physicians to speak to patients with motor impairment," he said. "There's a lot of interest so we don't want it to come in a big bottleneck right before the study we'll be doing."

Synchron received U.S. authorization for preliminary testing in July 2021 and has implanted its device in six patients. Prior testing in four patients in Australia showed no serious adverse side effects, the company has reported. Synchron will be analyzing the U.S. data to prepare for the larger study, while awaiting authorization from the U.S. Food and Drug Administration to proceed, Oxley said. Synchron and the FDA declined to comment on the expected timing of that decision. The company aims to include patients who are paralyzed due to the neurodegenerative disease ALS (amyotrophic lateral sclerosis), stroke and multiple sclerosis, Oxley said. [...]

Synchron's device is delivered to the brain via the large vein that sits next to the motor cortex in the brain instead of being surgically implanted into the brain cortex like Neuralink's. The FDA has asked Synchron to screen stroke patients using a non-invasive test to determine whether they would respond to an implant, Oxley said. "They want to expand the market to people who have had a stroke severe enough to cause paralysis because if limited to quadriplegia, the market is way too small to be sustainable," Kip Ludwig, former program director for neural engineering at the U.S. National Institutes of Health, said of Synchron. In 2020, Synchron reported that patients, opens new tab in its Australian study could use its first-generation device to type an average of 16 characters per minute. That's better than non-invasive devices that sit atop the head and record the electrical activity of the brain, which have helped people type up to eight characters per minute, but not the leap forward that is hoped for with an implant, Ludwig said. Oxley would not say whether typing has gotten faster or offer any other details from the ongoing U.S. trial. Reuters notes that Synchron's investors include billionaires Jeff Bezos and Bill Gates. It's competing with Elon Musk's Neuralink brain implant startup and claims it's farther along in the process of testing its device.

Earlier this year, Neuralink said it implanted a chip in its first human patient. It later said the patient fully recovered and was able to control a computer mouse using their thoughts.

"Varda Space Industries has closed a massive tranche of funding," reports TechCrunch, "just weeks after its first drug manufacturing capsule returned from orbit."

Varda has now raised $145 million to date, the article points out, and the $90 million in new Series B funding "marks an inflection point for the company, which is now gearing up to scale from the initial demonstration mission to a regular set of missions carrying customer payloads, Varda founder Delian Asparouhov told TechCrunch." El Segundo-based Varda was founded in 2021 by Asparouhov, who is also a partner at Founders Fund, and Will Bruey, a spacecraft engineer who cut his teeth at SpaceX. The pair had an audacious goal to commercialize what until very recently was promising but ultimately small-scale research into the effects of microgravity on pharmaceutical crystals... Astronauts have been conducting protein crystallization experiments in space for decades on the International Space Station and before that, the Space Shuttle. But the business case for expanding this research has never materialized — until now...

Part of the reason Varda is possible today is due to the availability of regular, low-cost rideshare launches from SpaceX and Rocket Lab's innovations in satellite bus manufacturing. Even beyond these external partnerships, the startup has made significant headway in its own right, as the success of the first mission showed: Their reentry capsule appears to have performed flawlessly and the experiment to reformulate the HIV medicine ritonavir was executed without a hitch, it says. Varda has also started publishing the results of its internal R&D efforts, including a scientific paper on its hyper-gravity (as opposed to microgravity) crystallization platform, which the startup developed as a sort of screening method prior to sending drugs to space. [The paper is titled "Gravity as a Knob for Tuning Particle Size Distributions of Small Molecules."] It's an entirely new field of research that takes advantage of the ability to truly unlock gravity as a variable in scientific experiments. "Over time, we will be able to generate data sets between both hyper-gravity and microgravity and start to show correlations," he said....

In a recent podcast appearance, he specified that the all-in initial mission cost around $12 million, which will drop to $5-6 million by mission 4 and $2.5 million or less by mission 10.) Larger capsules are also in the longer-term pipeline, though also not until the 2027 time frame. Asparouhov also confirmed that pharmaceuticals will be Varda's sole focus for the next 10-20 (or more) years, based on the company's conviction that pharmaceutical products will generate more economic value compared to other materials. A lot of that comes down to the fact that there are a significant set of drugs that require only a "seed" of the material that can only be made in microgravity, and the rest of the drug formulation can be completed here on Earth...

The company is also aiming to improve the processing capabilities of the on-board pharmaceutical reactor. The first mission carried just one drug protein, but in the future the company hopes to process multiple drug products that could be run through different processing regimes. In the future, other missions could carry larger reactors for drugs that do need more than the "seed" crystal, and those mission profiles would be closer to something like mass manufacturing.
Varda already has "a handful" of signed contracts with biotech companies, according to the article — and Varda's next manufacturing mission "will launch later this year."